HER2-positive Metastatic Breast Cancer in Kazakhstan
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Planned study population consists of approximately 240 adult patients with HER2-positive mBC receiving anti-HER2 therapy in 12 oncological centers (in each center it is expected to recruit about 20 patients) in different regions in order to provide representative study sample. Patients will be included consecutively from the least recent diagnosis (within defined time period). Planned retrospective follow-up period for 1 patient is a period starting from the date of mBC diagnosis until end study or until patient's death, whichever occurs first. End of study will be at least 12 months after the latest date of mBC diagnosis to ensure all patients have the opportunity to contribute at least 12 months of data.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznanie raka piersi z przerzutami między 1 stycznia 2022 a 31 grudnia 2023
- •Pacjent otrzymuje lub rozpoczął leczenie skierowane na receptor HER2 (poza trastuzumab deruksetekanem)
- •Dostępne dane medyczne z co najmniej 24 miesięcy od momentu rozpoznania przerzutów
- •Wiek co najmniej 18 lat
✗ Disqualifies
- •Inne nowotwory złośliwe w okresie od rozpoznania przerzutów
- •Pacjent otrzymywał trastuzumab deruksetekan
- •Uczestnictwo w badaniu klinicznym od momentu rozpoznania
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 99 Years
- Last updated (source)
- October 8, 2026
- Sex
- No restrictions
Locations (12)
Research Site
Oral, Kazakhstan
Research Site
Aktobe, Kazakhstan
Research Site
Almaty, Kazakhstan
Research Site
Almaty, Kazakhstan
Research Site
Astana, Kazakhstan
Research Site
Astana, Kazakhstan
Research Site
Karaganda, Kazakhstan
Research Site
Petropavl, Kazakhstan
Research Site
Semey, Kazakhstan
Research Site
Shymkent, Kazakhstan
Research Site
Shymkent, Kazakhstan
Research Site
Taraz, Kazakhstan
Trial contact
AstraZeneca Clinical Study Information Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.